Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HighLife SAS
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb looks back at ADA 2023 highlights and her interviews with diabetes company execs. Reed Miller discusses his Cardio Conversation with Volta Medical and Hannah Daniel discusses the FDA’s Clinical Decision Support Software final guidance.
Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.
Edwards has temporarily paused the FORTIS clinical program evaluating a new transcatheter mitral valve to resolve valve thrombosis issues that emerged in the first 20 patients.
The US heart valve treatments market will reach $1.7 billion by 2019, driven by advances in percutaneous heart valve repair and replacement products and a growing number of competitors entering this space. With US sales of transcatheter aortic valve replacement systems set to almost triple in the next several years, the combined US market for products to treat heart valve disorders is expected to grow at a CAGR of 7.7%.
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
- HighLife Medica
- HighLife S.A.S.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.